Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGENNASDAQ:EDITNASDAQ:MOLNNASDAQ:TROV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$4.97+5.8%$3.32$1.38▼$18.74$137.77M1.43662,965 shs258,457 shsEDITEditas Medicine$2.08+5.3%$1.56$0.91▼$6.05$172.87M2.12.57 million shs1.34 million shsMOLNMolecular Partners$3.92+2.1%$3.89$3.36▼$12.70$158.27M1.1117,694 shs996 shsTROVCardiff Oncology$3.81+0.5%$16.75$0.70▼$3.46$41.95M1.04648,892 shs998,339 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus0.00%-21.01%+35.06%+164.04%-69.60%EDITEditas Medicine0.00%+3.14%+30.46%+39.72%-61.07%MOLNMolecular Partners0.00%+5.22%+0.81%-3.83%-42.82%TROVCardiff Oncology0.00%-1.80%+38.55%-4.75%+41.11%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGENAgenus4.0167 of 5 stars3.23.00.04.62.11.70.6EDITEditas Medicine4.234 of 5 stars3.12.00.04.22.82.51.3MOLNMolecular Partners2.8813 of 5 stars3.85.00.00.02.20.00.6TROVCardiff OncologyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGENAgenus 2.33Hold$14.00181.46% UpsideEDITEditas Medicine 2.29Hold$5.36158.49% UpsideMOLNMolecular Partners 3.50Strong Buy$12.00206.12% UpsideTROVCardiff Oncology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TROV, EDIT, MOLN, and AGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025AGENAgenusRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$4.00 ➝ $6.006/4/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$25.005/13/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/13/2025AGENAgenusRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$3.00 ➝ $4.005/13/2025EDITEditas MedicineRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $4.004/30/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/29/2025EDITEditas MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$3.004/21/2025AGENAgenusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/18/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGENAgenus$99.52M1.37N/AN/A($7.78) per share-0.64EDITEditas Medicine$35.84M4.85N/AN/A$4.27 per share0.49MOLNMolecular Partners$2.23M70.91N/AN/A$5.41 per share0.72TROVCardiff Oncology$250K167.81N/AN/A$0.94 per share4.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGENAgenus-$245.76M-$8.67N/AN/AN/A-145.89%N/A-85.68%8/6/2025 (Estimated)EDITEditas Medicine-$153.22M-$3.04N/AN/AN/A-340.96%-80.13%-50.99%8/6/2025 (Estimated)MOLNMolecular Partners-$69.04M-$1.92N/AN/AN/A-1,043.01%-39.31%-35.46%8/25/2025 (Estimated)TROVCardiff Oncology-$16.41M-$2.80N/A∞N/A-3,688.31%-202.00%-122.92%N/ALatest TROV, EDIT, MOLN, and AGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025MOLNMolecular Partners-$0.3855-$0.50-$0.1145-$0.50N/AN/A5/12/2025Q1 2025AGENAgenus-$1.61-$1.03+$0.58-$1.03$26.38 million$24.07 million5/12/2025Q1 2025EDITEditas Medicine-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGENAgenusN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/ATROVCardiff OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGENAgenusN/A0.190.19EDITEditas MedicineN/A3.753.75MOLNMolecular PartnersN/A14.3314.33TROVCardiff Oncology0.122.372.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGENAgenus61.46%EDITEditas Medicine71.90%MOLNMolecular Partners26.55%TROVCardiff Oncology9.99%Insider OwnershipCompanyInsider OwnershipAGENAgenus5.50%EDITEditas Medicine2.10%MOLNMolecular Partners5.93%TROVCardiff Oncology0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGENAgenus44027.42 million22.38 millionOptionableEDITEditas Medicine23083.71 million80.98 millionOptionableMOLNMolecular Partners18040.38 million37.97 millionNot OptionableTROVCardiff OncologyN/A11.01 millionN/ANot OptionableTROV, EDIT, MOLN, and AGEN HeadlinesRecent News About These CompaniesCardiff Oncology, Inc. (CRDF) Reports 40% Response Rate in mTNBC Trial of Onvansertib + PaclitaxelJune 3, 2025 | insidermonkey.comWhy Cardiff Oncology, Inc.’s (CRDF) Stock Is Up 6.08%April 29, 2025 | aaii.comCardiff Oncology announces second patent for onvansertib combinationApril 24, 2025 | markets.businessinsider.comCardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve PatientsApril 23, 2025 | tmcnet.comCardiff Oncology (NASDAQ:CRDF) Stock, Option ChainApril 23, 2025 | benzinga.comIs Cardiff Oncology, Inc. (CRDF) The Hot Biotech Stock Under $5?March 26, 2025 | insidermonkey.comCardiff Oncology’s Earnings Call: Optimism Amid ChallengesFebruary 28, 2025 | tipranks.comWilliam Blair Keeps Their Buy Rating on Cardiff Oncology (CRDF)February 27, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX) and Cardiff Oncology (CRDF)February 27, 2025 | markets.businessinsider.comWhy Cardiff Oncology, Inc.’s (CRDF) Stock Is Up 15.07%January 31, 2025 | aaii.comCardiff Oncology Inc (CRDF) Stock: More Robust Than the Numbers Suggest?December 14, 2024 | bovnews.comCardiff Oncology Inc (CRDF) Stock: Surpassing Expectations in the Market?December 14, 2024 | bovnews.comCardiff Oncology announces positive colorectal data and $40m stock oversubscriptionDecember 11, 2024 | msn.comCardiff unveils positive Phase 2 data for colorectal cancer drug, $40M offeringDecember 10, 2024 | endpts.comCardiff stock soars on onvansertib data, $40M direct offeringDecember 10, 2024 | msn.comCardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct OfferingDecember 10, 2024 | tmcnet.comStock Surge, Strong Data: Is Cardiff Oncology (CRDF) on the Brink of a Major Breakthrough?December 10, 2024 | bovnews.comCardiff Oncology Reports Positive Q3 2024 Results and Clinical ProgressNovember 9, 2024 | markets.businessinsider.comCardiff Oncology Reports Third Quarter 2024 Results and Provides Business UpdateNovember 8, 2024 | markets.businessinsider.comWhat’s Fueling Cardiff Oncology Inc (CRDF) Stock’s 7.23% Gain Above Its 200-Day SMA?November 2, 2024 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAlphabet Stock Lags—But Waymo May Be Its Hidden DriverBy Gabriel Osorio-Mazilli | May 25, 2025View Alphabet Stock Lags—But Waymo May Be Its Hidden DriverTROV, EDIT, MOLN, and AGEN Company DescriptionsAgenus NASDAQ:AGEN$4.97 +0.27 (+5.83%) As of 12:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Editas Medicine NASDAQ:EDIT$2.08 +0.11 (+5.33%) As of 12:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Molecular Partners NASDAQ:MOLN$3.92 +0.08 (+2.08%) As of 12:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Cardiff Oncology NASDAQ:TROVCardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 2 Reasons Adobe Stock Is Ready to Rally This Year AMD Accelerates Stack Development: Share Price to Follow Alphabet Enters a Bull Market: Is It Time to Buy? Micron Joins Latest $200 Billion United States Investment Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Tariff Talks Advance, What Taiwan Semiconductor Can Deliver Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
